New Systemic Therapies in Hepatocellular Carcinoma

Course Information

The learner will receive 0.5 credits upon selecting and completing the individual course.

- For over a decade, sorafenib was the only systemic agent available for the treatment of advanced hepatocellular carcinoma (HCC). However, the past 2.5 years has added 6 additional agents. In this Clinical Forum^SM, our multidisciplinary expert roundtable convenes to discuss their collaborative care strategies for first and subsequent line management of HCC using case-based scenarios.

Summary


Cost:	FREE


Credit Offered:	No Credit Offered

Create Account